Panorama Medicine, a Bala Cynwyd genomics and artificial intelligence company, has raised $2 million in an equity financing deal, writes John George for the Philadelphia Business Journal.

The company was founded three years ago by CEO Mingfu Zhu, Yi Xing, and Douglas Black.

Prior to the founding of Panorama, Zhu was an executive with two genomics and gene sequencing companies from China. Xing serves as the director of the Center for Computational and Genomic Medicine at Children’s Hospital of Philadelphia. Meanwhile Black works as a professor at UCLA in the department of microbiology, immunology, and molecular genetics.

Panorama is developing therapeutic interventions for ribonucleic acid defects in disease by combining genomics with computing-powered drug discovery. Genomics is the study of genes and their functions.

The company’s proprietary drug-discovery technology platform PANACEA targets diseases that are treatable through the modulation of RNA splicing.

Two years ago, the company managed to raise $3.9 million in a seed round that was led by WI Harper Group, a San Francisco venture capital firm. ZhenFund and Delian Capital are among the company’s other investors.

Read more about Panorama Medicine at the Philadelphia Business Journal by clicking here